Mabro 2000.

Methods	RCT
Participants	Any patients with paediatric malignancy excluding cerebral tumours associated with vomiting Receiving moderately emetogenic chemotherapy: carboplatin (>= 500 mg/m²) cyclophosphamide (>= 500 to 900 mg/m²) in combination with other agents ifosfamide (1 to 2.4 g/m²) actinomycin D (>= 1.5 mg/m²) cisplatin (20 to 49 mg/m²) methotrexate (> 8 g/m²) adriamycin (>= 60 mg/m²) cytarabine (1 to 2.9 g/m²) OR highly emetogenic chemotherapy: cyclophosphamide (>= 1000 mg/m²) cisplatin (>= 50 mg/m²) ifosfamide (>= 2.5 g/m²) nitrogen mustard (> 6 mg/m²) dacarbazine (> 200 mg/m²) cytarabine (>= 3 g/m²) Patients were excluded if: received more than 1 course of chemotherapy in preceding year, radiation therapy in preceding 7 days or during course of study, emetogenic chemotherapy in preceding 7 days, persistent nausea or vomiting in preceding 48 hours, a food intolerance in preceding 4 days, intestinal obstruction, corticosteroids outside of chemotherapy treatment, other antiemetic treatments, cerebral tumours associated with vomiting, liver enzymes outside of specified range Mean age 7.8 years (range 1 year to 16 years). 177/294 participants were male
Interventions	143 participants received 20 µg/kg oral granisetron (orange flavoured) ‐ diluted to 0.2 mg/ml and given 1 hour before and again 6 to 12 hours after the start of chemotherapy on each day of chemotherapy for 1 to 5 days (depending on chemotherapy regimen) 151 participants received 40 µg/kg oral granisetron (orange flavoured) ‐ diluted to 0.2 mg/ml and given 1 hour before and again 6 to 12 hours after the start of chemotherapy on each day of chemotherapy for 1 to 5 days (depending on chemotherapy regimen)
Outcomes	Number of vomits recorded every 6 hours for each 24‐hour period. Nausea assessed by unvalidated self/parent report using a scale of "none, mild, moderate, severe"
Notes	—
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	States "randomised"
Allocation concealment (selection bias)	Unclear risk	Not stated
Blinding (performance bias and detection bias) Acute nausea	High risk	Not reported
Blinding (performance bias and detection bias) Acute vomiting	Low risk	States "double blind" Blinding of care provider: yes Blinding of participant: yes Blinding of outcome assessors: yes
Blinding (performance bias and detection bias) Other outcomes	Low risk	States "double blind" Blinding of care provider: yes Blinding of participant: yes Blinding of outcome assessors: yes
Incomplete outcome data (attrition bias) All outcomes	Low risk	Intention‐to‐treat analysis reported by day
Selective reporting (reporting bias)	Low risk	—
Other bias	Low risk	Randomisation stratified by emetogenic level of chemotherapy